Comparative Efficacy of Inhaled Corticosteroid and Long-acting Beta Agonist Combinations in Preventing COPD Exacerbations: a Bayesian Network Meta-analysis

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2014 May 30

PMID 24872685

Citations 9

Authors

Yuji Oba

Nazir A Lone

Affiliations

Soon will be listed here.

Abstract

Background: A combination therapy with inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA) is recommended in severe chronic obstructive pulmonary disease (COPD) patients experiencing frequent exacerbations. Currently, there are five ICS/LABA combination products available on the market. The purpose of this study was to systematically review the efficacy of various ICS/LABA combinations with a network meta-analysis.

Methods: Several databases and manufacturer's websites were searched for relevant clinical trials. Randomized control trials, at least 12 weeks duration, comparing an ICS/LABA combination with active control or placebo were included. Moderate and severe exacerbations were chosen as the outcome assessment criteria. The primary analyses were conducted with a Bayesian Markov chain Monte Carlo method.

Results: Most of the ICS/LABA combinations reduced moderate-to-severe exacerbations as compared with placebo and LABA, but none of them reduced severe exacerbations. However, many studies excluded patients receiving long-term oxygen therapy. Moderate-dose ICS was as effective as high-dose ICS in reducing exacerbations when combined with LABA.

Conclusion: ICS/LABA combinations had a class effect with regard to the prevention of COPD exacerbations. Moderate-dose ICS/LABA combination therapy would be sufficient for COPD patients when indicated. The efficacy of ICS/LABA combination therapy appeared modest and had no impact in reducing severe exacerbations. Further studies are needed to evaluate the efficacy of ICS/LABA combination therapy in severely affected COPD patients requiring long-term oxygen therapy.

Citing Articles

Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD).

Mills H, Acquah R, Tang N, Cheung L, Klenk S, Glassen R Emerg Med Int. 2022; 2022:2593740.

PMID: 35899144 PMC: 9313957. DOI: 10.1155/2022/2593740.

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone.

Price D, Henley W, Cancado J, Fabbri L, Kerstjens H, Papi A Int J Chron Obstruct Pulmon Dis. 2022; 17:355-370.

PMID: 35210765 PMC: 8858000. DOI: 10.2147/COPD.S342357.

Development and Practical Application of a Multiple-Criteria Decision Analysis Framework on Respiratory Inhalers: Is It Always Useful in the MOH Malaysia Medicines Formulary Listing Context?.

Yong Y, Dom S, Ahmad Saad N, Lajis R, Md Yusof F, Rahaman J MDM Policy Pract. 2021; 6(1):2381468321994063.

PMID: 33855190 PMC: 8013673. DOI: 10.1177/2381468321994063.

Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?.

Tashkin D, Strange C Int J Chron Obstruct Pulmon Dis. 2018; 13:2587-2601.

PMID: 30214177 PMC: 6118265. DOI: 10.2147/COPD.S172240.

The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease.

Beeh K Tuberc Respir Dis (Seoul). 2016; 79(4):241-247.

PMID: 27790275 PMC: 5077727. DOI: 10.4046/trd.2016.79.4.241.

References

Goldenberg M . Pharmaceutical approval update. P T. 2013; 38(7):389-403. PMC: 3776487. View

Vestbo J, Hurd S, Agusti A, Jones P, Vogelmeier C, Anzueto A . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012; 187(4):347-65. DOI: 10.1164/rccm.201204-0596PP. View

Mahler D, Wire P, Horstman D, Chang C, Yates J, Fischer T . Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166(8):1084-91. DOI: 10.1164/rccm.2112055. View

Toft N, Innocent G, Gettinby G, Reid S . Assessing the convergence of Markov Chain Monte Carlo methods: an example from evaluation of diagnostic tests in absence of a gold standard. Prev Vet Med. 2007; 79(2-4):244-56. DOI: 10.1016/j.prevetmed.2007.01.003. View

Kardos P, Wencker M, Glaab T, Vogelmeier C . Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 175(2):144-9. DOI: 10.1164/rccm.200602-244OC. View

Hanania N, Darken P, Horstman D, Reisner C, Lee B, Davis S . The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003; 124(3):834-43. DOI: 10.1378/chest.124.3.834. View

Rennard S, Tashkin D, McElhattan J, Goldman M, Ramachandran S, Martin U . Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009; 69(5):549-65. PMC: 3580134. DOI: 10.2165/00003495-200969050-00004. View

Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A . Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361(9356):449-56. DOI: 10.1016/S0140-6736(03)12459-2. View

Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S . Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003; 21(1):74-81. DOI: 10.1183/09031936.03.00031402. View

10.

Zhong N, Zheng J, Wen F, Yang L, Chen P, Xiu Q . Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Curr Med Res Opin. 2011; 28(2):257-65. DOI: 10.1185/03007995.2011.636420. View

11.

Nannini L, Poole P, Milan S, Holmes R, Normansell R . Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013; (11):CD003794. PMC: 6485527. DOI: 10.1002/14651858.CD003794.pub4. View

12.

Sharafkhaneh A, Southard J, Goldman M, Uryniak T, Martin U . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2011; 106(2):257-68. DOI: 10.1016/j.rmed.2011.07.020. View

13.

Tashkin D, Doherty D, Kerwin E, Matiz-Bueno C, Knorr B, Shekar T . Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis. 2012; 7:73-86. PMC: 3276258. DOI: 10.2147/COPD.S29444. View

14.

Ferguson G, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C . Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med. 2008; 102(8):1099-108. DOI: 10.1016/j.rmed.2008.04.019. View

15.

Kerwin E, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N . A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med. 2013; 107(4):560-9. DOI: 10.1016/j.rmed.2012.12.014. View

16.

Halbert R, Natoli J, Gano A, Badamgarav E, Buist A, Mannino D . Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006; 28(3):523-32. DOI: 10.1183/09031936.06.00124605. View

17.

Dransfield M, Bourbeau J, Jones P, Hanania N, Mahler D, Vestbo J . Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2014; 1(3):210-23. DOI: 10.1016/S2213-2600(13)70040-7. View

18.

Calverley P, Anderson J, Celli B, Ferguson G, Jenkins C, Jones P . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8):775-89. DOI: 10.1056/NEJMoa063070. View

19.

Tashkin D, Rennard S, Martin P, Ramachandran S, Martin U, Silkoff P . Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008; 68(14):1975-2000. DOI: 10.2165/00003495-200868140-00004. View

20.

Martinez F, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L . Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med. 2013; 107(4):550-9. DOI: 10.1016/j.rmed.2012.12.016. View